LINC00092: A Potential Drug Target and Biomarker (G100188953)

Target Name: LINC00092

NCBI ID: G100188953

LINC00092

Other Name(s): Long intergenic non-protein coding RNA 92 | bA346B7.1 | NCRNA00092 | long intergenic non-protein coding RNA 92

LINC00092: A Potential Drug Target and Biomarker

LINC00092 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the myeloid-derived suppressor (MDS) gene, which is involved in the development of many types of cancer. LINC00092 has been shown to play a critical role in the regulation of cell growth, differentiation, and survival.

The MDS gene is a member of the TCF-1 gene family, which is known for their role in the regulation of stem cell proliferation and differentiation. LINC00092 is a non-coding RNA molecule that is derived from the TCF-1 gene and has been shown to have similar DNA binding properties to TCF-1.

LINC00092 has been shown to play a critical role in the regulation of myeloid-derived suppressor (MDS) gene expression. MDS cells are a type of cancer cell that have the ability to give rise to many different types of leukemia. LINC00092 has been shown to help control the production of MDS cells by regulating the activity of the TCF-1 gene.

In addition to its role in the regulation of MDS cells, LINC00092 has also been shown to play a critical role in the regulation of normal cell growth and differentiation. It has been shown to help control the production of cells that are resistant to programmed cell death, which is a process that helps prevent the development of cancer.

The potential drug target for LINC00092 is the Myeloid-derived suppressor (MDS) gene, which is involved in the development of many types of cancer. MDS cells are a type of cancer cell that have the ability to give rise to many different types of leukemia. LINC00092 has been shown to help control the production of MDS cells by regulating the activity of the TCF-1 gene.

LINC00092 has also been shown to play a critical role in the regulation of normal cell growth and differentiation. It has been shown to help control the production of cells that are resistant to programmed cell death, which is a process that helps prevent the development of cancer.

The potential use of LINC00092 as a drug target is based on the fact that it has been shown to play a critical role in the regulation of MDS cells and has the potential to disrupt the development of MDS cells. This suggests that LINC00092 could be an effective target for the treatment of MDS-related cancers.

In conclusion, LINC00092 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the myeloid-derived suppressor (MDS) gene and has been shown to play a critical role in the regulation of cell growth, differentiation, and survival. Further research is needed to determine the full potential of LINC00092 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 92

The "LINC00092 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00092 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets